Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results , with sales up 1.3% year on year to $321.2 million ...

Bio-Techne's (TECH) fiscal Q4 organic revenue growth of 3% is consistent with the progressive improvement story reflected in management's expectation of fiscal 2027 being a roughly 6% sales growth ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

"Bio-Techne ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

An integrated assay using proprietary RNAscope™ and miRNAscope™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. Small regulatory RNAs, ...